The Claim
In high-risk cardiovascular patients, evolocumab administered at a dose of 140mg reduces low-density lipoprotein cholesterol (LDL-c) by 61.09% compared to placebo after a median of 24 weeks, with a 95% confidence interval of -64.81% to -57.38%, demonstrating a potent and consistent lipid-lowering effect as observed across multiple randomized trials.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
A drug called evolocumab, when given every two weeks, cuts bad cholesterol by more than 60% in people at high risk for heart problems — and that result has shown up consistently in several major studies.
See the scientific wording
Evolocumab, administered at 140mg, reduces low-density lipoprotein cholesterol (LDL-c) by 61.09% compared to placebo after a median of 24 weeks in high-risk cardiovascular patients, with a 95% confidence interval of -64.81% to -57.38%, demonstrating a potent and consistent lipid-lowering effect across multiple randomized trials.
What the research says
1 studyThe study looked at the same medicine, dose, and type of patients as the claim, and found exactly the same result for lowering bad cholesterol.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.